Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Long-term survival after laparoscopic versus open resection for colorectal liver...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
Long-term survival after laparoscopic versus open resection for colorectal liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
No difference in survival between laparoscopic surgery and open surgery in color...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer wi...
Prof Arnaud Mejean - Paris Descartes University, Paris, France
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )
3 Jun 2019
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitin...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junc...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spa...
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
1 Jun 2019
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemothera...
Dr Richard Schilsky and Dr Josep Tabernero
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )
1 Jun 2019
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or g...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Sp...
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )
1 Jun 2019
IMPACT: Improving Management of Advanced Colorectal Tumours
Mr Steve Clark, Patient Advocate for Bowel Cancer UK and Expert Patient for ACPG...
IMPACT: Improving Management of Advanced Colorectal Tumours ( Mr Steve Clark, Patient Advocate for Bowel Cancer UK and Expert Patient for ACPGBI )
21 May 2019
Pre-operative radiation for pancreatic cancer
Prof Sunil Krishnan - MD Anderson Cancer Center, Houston, USA
Pre-operative radiation for pancreatic cancer ( Prof Sunil Krishnan - MD Anderson Cancer Center, Houston, USA )
9 May 2019
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk
Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA
Second-line and beyond in mCRC: Optimising the benefit and reducing the risk ( Prof Mohamed Salem - Georgetown University Hospital, Washington D.C., USA )
9 May 2019
Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus ...
Prof John Marshall - Georgetown University Hospital, Washington D.C., USA
Optimum duration of adjuvant treatment of stage III colorectal cancer: 3 versus 6 months ( Prof John Marshall - Georgetown University Hospital, Washington D.C., USA )
9 May 2019